Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon May 23, 2023 4:27pm
138 Views
Post# 35460856

RE:Winning??

RE:Winning??bluemoons20 there are endless outcomes that are possible and each having a projected share price:

Replicel and Shiseido strike a deal to co-develop RCH-01.
Shiseido buys out the rights to RCH-01.
Shiseido buys out Replicel.
Replicel wins the Arbitration and recovers the marketing rights for RCH-01 in Asia
Replicel wins the arbitration, recovers the marketing rights to RCH-01 in Asia and awarded a monetary compensation.
Replicel wins the arbitration and is bought out by a large pharma company.
Shiseido wins the arbitration and moves forward with marketing RCH-01 in Asia without Replicel.
Shiseido wins the arbitration and Replicel files for bankrupty.

I am sure there are many more scenarios but these are the ones that come to mind. The share values for each of the above at best are just a guess.  The range is from $0.00 - $3.00.  I can't see in the next year if any of the above come to pass that the share price gets beyond $3.00 with close to 75,000,000 Shares,Warrants and Options outstanding.  Down the road with divine intervention we may get beyond $3.00.





<< Previous
Bullboard Posts
Next >>